Department of Pharmaceutics, School of Pharmacy, Shaheed Beheshti University of Medical Sciences, Tehran, Iran.
J Control Release. 2010 Dec 1;148(2):177-86. doi: 10.1016/j.jconrel.2010.08.026. Epub 2010 Aug 26.
In the treatment of peritoneal carcinomatosis, systemic chemotherapy is not quite effective due to the poor penetration of cytotoxic agents into the peritoneal cavity, whereas intraperitoneal administration of chemotherapeutic agents is generally accompanied by quick absorption of the free drug from the peritoneum. Local delivery of drugs with controlled-release delivery systems like liposomes could provide sustained, elevated drug levels and reduce local and systemic toxicity. In order to achieve an ameliorated liposomal formulation that results in higher peritoneal levels of the drug and retention, vesicles composed of different phospholipid compositions (distearoyl [DSPC]; dipalmitoyl [DPPC]; or dimiristoylphosphatidylcholine [DMPC]) and various charges (neutral; negative, containing distearoylphosphatidylglycerol [DSPG]; or positive, containing dioleyloxy trimethylammonium propane [DOTAP]) were prepared at two sizes of 100 and 1000nm. The effect of surface hydrophilicity was also investigated by incorporating PEG into the DSPC-containing neutral and charged liposomes. Liposomes were labeled with (99m)Tc and injected into mouse peritoneum. Mice were then sacrificed at eight different time points, and the percentage of injected radiolabel in the peritoneal cavity and the tissue distribution in terms of the percent of the injected dose/gram of tissue (%ID/g) were obtained. The ratio of the peritoneal AUC to the free label ranged from a minimum of 4.95 for DMPC/CHOL (cholesterol) 100nm vesicles to a maximum of 24.99 for DSPC/CHOL/DOTAP 1000nm (DOTAP 1000) vesicles. These last positively charged vesicles had the greatest peritoneal level; moreover, their level remained constant at approximately 25% of the injected dose from 2 to 48h. Among the conventional (i.e., without PEG) 100nm liposomes, the positively charged vesicles again showed the greatest retention. Incorporation of PEG at this size into the lipid structures augmented the peritoneal level, particularly for negatively charged liposomes. The positively charged PEGylated vesicles (DOTAP/PEG 100) had the second-greatest peritoneal level after DOTAP 1000; however, their peritoneal-to-blood AUC ratio was low (3.05). Overall, among the different liposomal formulations, the positively charged conventional liposomes (100 and 1000nm) provided greater peritoneal levels and retention. DOTAP/PEG100 may also be a more efficient formulation because this formulation can provide a high level of anticancer drug into the peritoneal cavity and also can passively target the primary tumor.
在治疗腹膜癌时,由于细胞毒性药物在腹腔内的渗透不良,全身化疗效果并不理想,而腹腔内给予化疗药物通常伴随着游离药物从腹膜的快速吸收。使用脂质体等控释药物传递系统局部给药可以提供持续升高的药物水平,减少局部和全身毒性。为了实现改良的脂质体制剂,从而导致药物在腹膜内水平升高和保留,由不同的磷脂组成(二硬脂酰[DSPC];棕榈酰[DPPC];或二肉豆蔻酰磷脂酰胆碱[DMPC])和不同电荷(中性;负,含二硬脂酰磷脂酰甘油[DSPG];或正,含二油酰氧基三甲基铵丙烷[DOTAP])的囊泡在两种尺寸 100nm 和 1000nm 下进行制备。通过将 PEG 掺入含 DSPC 的中性和带电脂质体中来研究表面亲水性的影响。用(99m)Tc 标记脂质体并注入小鼠腹膜。然后在八个不同时间点处死小鼠,并获得腹腔内注射放射性标记的百分比和组织分布(以注射剂量/克组织的百分比[ID/g]表示)。腹膜 AUC 与游离标记物的比值范围从最小的 4.95(100nm DMPC/CHOL 囊泡)到最大的 24.99(1000nm DSPC/CHOL/DOTAP 囊泡)。最后,这些带正电荷的囊泡具有最高的腹膜水平;此外,从 2 小时到 48 小时,它们的水平保持在约 25%的注射剂量不变。在常规(即无 PEG)100nm 脂质体中,带正电荷的囊泡再次显示出最大的保留。在这种大小的脂质结构中掺入 PEG 增加了腹膜水平,特别是对于带负电荷的脂质体。带正电荷的 PEG 化囊泡(DOTAP/PEG 100)在 DOTAP 1000 之后具有第二高的腹膜水平;然而,它们的腹膜-血液 AUC 比值较低(3.05)。总的来说,在不同的脂质体制剂中,带正电荷的常规脂质体(100nm 和 1000nm)提供了更高的腹膜水平和保留。DOTAP/PEG100 也可能是一种更有效的制剂,因为这种制剂可以将高水平的抗癌药物递送到腹膜腔中,并且还可以被动靶向原发性肿瘤。